Response to a monovalent 2009 influenza A (H1N1) vaccine. - sprookjes - yvandenbroek - TriplyDB

Response to a monovalent 2009 influenza A (H1N1) vaccine.

Response to a monovalent 2009 influenza A (H1N1) vaccine.

http://www.wikidata.org/entity/Q30380581

about

Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination The Role of CD4 T Cell Memory in Generating Protective Immunity to Novel and Potentially Pandemic Strains of Influenza Influenza virus vaccines: lessons from the 2009 H1N1 pandemic Structure and Receptor binding properties of a pandemic H1N1 virus hemagglutinin Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities Seroprevalence of pandemic influenza H1N1 in Ontario from January 2009-May 2010 Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine Optimal pandemic influenza vaccine allocation strategies for the Canadian population Vaccine procurement during an influenza pandemic and the role of Advance Purchase Agreements: Lessons from 2009-H1N1.Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.The 2009 influenza A (H1N1) pandemic: what have we learned in the past 6 months.2009 pandemic influenza in India.Spontaneous reporting of adverse events following pandemic influenza A (H1N1) immunization in a reference center in the State of São Paulo, Brazil.Comparative analysis of antibody induction and protection against influenza virus infection by DNA immunization with HA, HAe, and HA1 in mice.Seroconversion of 2009 pandemic influenza A (H1N1) vaccination in kidney transplant patients and the influence of different risk factors.Swine flu: lessons we need to learn from our global experience Immune activation and viral replication after vaccination with an influenza A H1N1 2009 vaccine in HIV-infected children receiving antiretroviral therapy.Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth.The long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 vaccine: Randomized, observer-masked, single-center clinical study.Influenza vaccination in immunocompromised patients: efficacy and safety.The pandemic influenza A (H1N1) 2009 vaccine does not increase the mortality rate of idiopathic interstitial pneumonia: a matched case-control study.Enhanced viral replication and modulated innate immune responses in infant airway epithelium following H1N1 infection.Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness.Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine.Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations Long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in mice Phase 1 study of pandemic H1 DNA vaccine in healthy adults Community awareness, use and preference for pandemic influenza vaccines in Pune, India Guidelines on management of human infection with the novel virus influenza A (H1N1)--a report from the Hospital das Clínicas of the University of São Paulo.How I treat influenza in patients with hematologic malignancies.Pandemic influenza A (H1N1) 2009: the experience of the first six months.Influenza A/H1N1_09: Australia and New Zealand's winter of discontent.

P2860

Q21560857-314C741C-C8DF-4845-B44D-1BE83879207B Q24600337-489DCD43-354C-493B-96C2-A93054F84491 Q24607378-12F06AA1-B809-4324-8E69-CD1558007768 Q26772701-CBFE596A-3D1C-43EB-80BF-B50693CEEB18 Q27027029-1D1FB7D9-6234-4D84-8381-81A6CFB28F34 Q27660366-43E93131-ADAD-4FEB-B29C-A074CD9B1864 Q28741469-5830FF3D-A80F-4AAD-A0FE-507CDF39A368 Q28742786-1A40FFCB-3A82-4FE0-B8F5-B25B7655EADF Q28742787-259D2E8B-3F7B-4540-9C19-0E635562082C Q28742920-9974F8A8-679B-47AD-BBFC-1D2325F2D649 Q28744349-A8CE2365-6CBE-430C-9ECA-DFC5E0F60038 Q28752312-5CFFD3F7-A455-4C29-9505-BCD48BE45CDD Q30203064-DCE6B3B6-D4BB-4E69-87DE-8A8FE7EBABC4 Q30224646-D012C602-5090-4467-AA0E-A98FB56F2684 Q30227033-0FE7B6F0-43D9-4396-A3E6-0BC8A93413F6 Q30227308-05511FF7-E1D0-4B9D-8F81-BCD1BA2F7C9A Q30352113-DA94B2F4-0E1A-4485-8B70-74BE9136C0E2 Q30354612-FEAEE1FB-7550-4B9F-9DD8-B471F7858FC9 Q30354634-F983994C-543A-4CE9-BCF1-74E00284C83C Q30354811-33B0E4EF-99FB-46CA-B840-3C4BE4AF44B7 Q30354991-576CB641-0859-4C11-8132-889FE025790C Q30355654-C7C4EAAD-39F0-42E8-9DCB-755070914C16 Q30357144-DA0112AF-E8D8-46D7-8D7D-C79F085615CC Q30357158-C67FAACF-1004-4C43-B21F-B4C07E309B7A Q30357303-3EAB25DF-1CBE-4719-9A59-0F12139217B9 Q30358640-4ECB69F7-1CF1-44C4-AD5A-3979516CEB7D Q30359671-70E836C9-E65C-47C5-AD4E-F2BDB7E2445B Q30361458-61788C69-FD49-4DB2-BFAD-11068F6264B2 Q30362883-77AD1738-7DB7-4241-8E60-67660E6A33A1 Q30363098-3EB7B336-A1A0-4E35-97B2-4F4392E3E672 Q30363689-9D87B29F-AAB0-463B-85A6-0D4DEF3EC260 Q30368247-86264076-68E1-4D94-BD7A-364EE8DFEE95 Q30369098-C79AB23F-6EA1-4BC7-A996-01B8BC008657 Q30370790-80E3CDFE-7422-4D68-8A6E-66F445A5D03B Q30373824-81D8D14F-0292-4644-9CAC-4FE3C4F75252 Q30376060-0535F0E8-C372-4F26-A53C-FE809598A4BB Q30381783-147E329F-5A20-43DA-94BF-85708EECCB8F Q30383456-359CFE44-A2CD-4722-9058-706121E43190 Q30383709-26A9C6F7-56A4-4231-8C0C-018713EBA1D5 Q30385337-8FB8FE37-19E4-46F3-956B-A06DCBBF7F38

P2860

Response to a monovalent 2009 influenza A (H1N1) vaccine.

http://www.wikidata.org/entity/Q30380581

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Response to a monovalent 2009 influenza A (H1N1) vaccine.

@ast

Response to a monovalent 2009 influenza A (H1N1) vaccine.

@en

type

label

Response to a monovalent 2009 influenza A (H1N1) vaccine.

@ast

Response to a monovalent 2009 influenza A (H1N1) vaccine.

@en

prefLabel

Response to a monovalent 2009 influenza A (H1N1) vaccine.

@ast

Response to a monovalent 2009 influenza A (H1N1) vaccine.

@en

P1433

Q30380581-FD828A21-DCC5-473E-A547-0F1ED73C6589

P1476

Q30380581-75983A52-550E-4208-A969-61694A9BDE3E

P2093

Q30380581-1D36A08A-EFA3-43FE-9C84-4697082EE255

Q30380581-32DB1A9E-45AC-4F18-980A-CE20CF348C02

Q30380581-606435DE-67CB-4F64-94A9-C58EEB3A47D2

Q30380581-85C5BC09-D80D-48C5-ABF8-8F370260E4A7

Q30380581-8A305012-5A09-43CE-860F-F19EB959671D

Q30380581-968416FF-E84C-46D1-A4F6-73B83B29645B

Q30380581-99970556-0B0A-4907-9559-17FED0E3028A

Q30380581-B59493B1-F1A7-4324-A637-3EB48819A9A4

Q30380581-C2FB4D80-1193-40AD-B5BE-BCA2FBC07C2C

P304

Q30380581-AED4D200-2A16-44E1-8A9C-77E619F686F5

P31

Q30380581-E1CCBEFF-F8F5-447F-B65B-2FDFEEB1092D

P356

Q30380581-2CE4B45A-791E-4169-AFB9-80EF97CA30F1

P407

Q30380581-20FE83C7-6A86-4B90-8675-BDA7ED0EF7FD

P433

Q30380581-2088B66A-1AB4-443C-9206-EFDDC727AEE6

P478

Q30380581-BC7F158B-FB71-49FA-B9D6-4B266F856DA2

P50

Q30380581-ED9D9BCE-6FAA-485E-9354-4C3E86636402

Q30380581-FD686BDF-557A-433D-993B-340E7FD9468D

P577

Q30380581-93066A1E-8592-4BE9-8E8D-A29378549089

P698

Q30380581-61CFFBC5-8D6C-45B8-B496-2A3F93BFF2A3

P356

P1433

The New England Journal of Medicine

P1476

Response to a monovalent 2009 influenza A (H1N1) vaccine

@en

P2093

Charmaine Gittleson

http://www.w3.org/2001/XMLSchema#string

Christine H Wichems

http://www.w3.org/2001/XMLSchema#string

Connie Leggio

http://www.w3.org/2001/XMLSchema#string

Diane Washington

http://www.w3.org/2001/XMLSchema#string

Gail Dawson

http://www.w3.org/2001/XMLSchema#string

Jillian Bennet

http://www.w3.org/2001/XMLSchema#string

Michael H Lai

http://www.w3.org/2001/XMLSchema#string

Russell L Basser

http://www.w3.org/2001/XMLSchema#string

Wilson Hu

http://www.w3.org/2001/XMLSchema#string

P304

2405-2413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0907413

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

361

http://www.w3.org/2001/XMLSchema#string

P50

Michael Greenberg

P577

2009-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19745216

http://www.w3.org/2001/XMLSchema#string